SynthesisBrain and behavior2026
Structural Volumetric Alterations in Parkinson's Disease With Mild Cognitive Impairment.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundParkinson's disease with mild cognitive impairment (PD-MCI) is a critical dementia prodrome, but its structural neuropathology remains incompletely defined. While hippocampal atrophy is established, volumetric changes in other subcortical structures are poorly characterized.
objectiveTo perform the first comprehensive meta-analysis quantifying gray matter volume alterations across six subcortical regions in PD-MCI.
methodsA systematic search of PubMed, Web of Science, Embase, and Cochrane (inception-June 2025) for studies reporting MRI volumetric data comparing PD-MCI and cognitively normal PD (PD-NC) was done. Random-effects models calculated pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs). Heterogeneity (I
resultsPD-MCI showed significant bilateral atrophy versus PD-NC in the hippocampus (total WMD = -0.65 cm
conclusionPD-MCI exhibits a distinct subcortical atrophy signature involving limbic-striato-thalamic networks, with right globus pallidus atrophy as a novel lateralized biomarker. Network-based imaging paradigms are advocated, requiring standardized protocols and longitudinal validation. SYSTEMATIC REVIEW REGISTRATION: Identifier PROSPERO (CRD420251051275).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.